Zacks Investment Research downgraded Trillium Therapeutics Inc. (NASDAQ:TRIL) to Sell in a report released today.
- Updated: February 12, 2017
Yesterday Trillium Therapeutics Inc. (NASDAQ:TRIL) traded 0.00% even at $5.75. The company’s 50-day moving average is $5.52 and its 200-day moving average is $9.91. The last stock close price is down -39.48% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time. 70,494 shares of the stock were exchanged, down from an average trading volume of 145,416
Zacks Investment Research has downgraded Trillium Therapeutics Inc. (NASDAQ:TRIL) to Sell in a report released on Thursday February 09, 2017.
See Chart Below
Trillium Therapeutics Inc. has a 52 week low of $4.50 and a 52 week high of $17.70 The company’s market cap is currently $0.
About Trillium Therapeutics Inc. (NASDAQ:TRIL)
Trillium Therapeutics Inc., an immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is SIRPaFc, an antibody-like fusion protein, which is in Phase I clinical trial that blocks the activity of CD47 to promote the macrophage-mediated killing of tumor cells in a range of cancers. It also develops CD200 monoclonal antibody that blocks the activity of CD200 to evade attack from the immune system. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.